JP2012510484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510484A5 JP2012510484A5 JP2011538906A JP2011538906A JP2012510484A5 JP 2012510484 A5 JP2012510484 A5 JP 2012510484A5 JP 2011538906 A JP2011538906 A JP 2011538906A JP 2011538906 A JP2011538906 A JP 2011538906A JP 2012510484 A5 JP2012510484 A5 JP 2012510484A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- minutes
- administration
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229960002707 bendamustine Drugs 0.000 claims 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 229960003511 macrogol Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- FUWVMBCPMRAWPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OCC(O)CO FUWVMBCPMRAWPG-UHFFFAOYSA-N 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical group Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08075915 | 2008-12-03 | ||
| EP08075915.2 | 2008-12-03 | ||
| PCT/EP2009/008857 WO2010063493A1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510484A JP2012510484A (ja) | 2012-05-10 |
| JP2012510484A5 true JP2012510484A5 (cg-RX-API-DMAC7.html) | 2013-01-24 |
| JP5778037B2 JP5778037B2 (ja) | 2015-09-16 |
Family
ID=40588059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538906A Active JP5778037B2 (ja) | 2008-12-03 | 2009-12-03 | ベンダムスチンの経口投与剤 |
Country Status (25)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2575784T3 (en) * | 2010-06-02 | 2018-10-15 | Astellas Deutschland Gmbh | ORAL DOSAGE FORMS OF BENDAMUSTIN |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| CN102375044B (zh) * | 2010-08-18 | 2015-04-08 | 重庆华邦胜凯制药有限公司 | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 |
| WO2013046223A1 (en) * | 2011-09-26 | 2013-04-04 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of bendamustine hydrochloride |
| CN116077644A (zh) * | 2011-10-31 | 2023-05-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| SI2656843T1 (sl) | 2012-04-26 | 2015-06-30 | Helmut Schickaneder | Estri bendamustina in povezane spojine ter njihova medicinska uporaba |
| MX2015005805A (es) * | 2012-11-12 | 2016-04-15 | Ignyta Inc | Derivados de bendamustina y métodos para utilizarlos. |
| MX362032B (es) | 2013-03-12 | 2019-01-04 | Cephalon Inc | Formulaciones nanoparticuladas y macroparticuladas. |
| JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
| JP6571657B2 (ja) | 2013-08-27 | 2019-09-04 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
| SG11202003098WA (en) | 2017-10-05 | 2020-05-28 | Tube Pharmaceuticals Gmbh | Oral bendamustine formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US132502A (en) * | 1872-10-22 | Improvement in machines for removing snow from railroads | ||
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US20060128777A1 (en) * | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
| CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
| CN101028249A (zh) * | 2007-04-12 | 2007-09-05 | 济南康泉医药科技有限公司 | 一种含新生血管抑制剂及烷化剂的抗癌组合物 |
| CN101045058A (zh) * | 2007-04-28 | 2007-10-03 | 济南帅华医药科技有限公司 | 一种含烷化剂及激素类药物的抗癌组合物 |
| CN101084876A (zh) * | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
| US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
-
2009
- 2009-12-03 HR HRP20140204AT patent/HRP20140204T1/hr unknown
- 2009-12-03 AU AU2009321745A patent/AU2009321745B2/en active Active
- 2009-12-03 DK DK09796303.7T patent/DK2367542T3/da active
- 2009-12-03 JP JP2011538906A patent/JP5778037B2/ja active Active
- 2009-12-03 PL PL09796303T patent/PL2367542T3/pl unknown
- 2009-12-03 UA UAA201106235A patent/UA102120C2/ru unknown
- 2009-12-03 EP EP09796303.7A patent/EP2367542B1/en active Active
- 2009-12-03 PT PT97963037T patent/PT2367542E/pt unknown
- 2009-12-03 CA CA2745525A patent/CA2745525A1/en not_active Abandoned
- 2009-12-03 CN CN201510849775.0A patent/CN105363037B/zh not_active Expired - Fee Related
- 2009-12-03 KR KR1020117015292A patent/KR101688038B1/ko not_active Expired - Fee Related
- 2009-12-03 EA EA201190011A patent/EA020354B1/ru unknown
- 2009-12-03 ES ES09796303.7T patent/ES2451540T3/es active Active
- 2009-12-03 SI SI200930877T patent/SI2367542T1/sl unknown
- 2009-12-03 US US13/132,263 patent/US20120003305A1/en not_active Abandoned
- 2009-12-03 NZ NZ592970A patent/NZ592970A/xx unknown
- 2009-12-03 CN CN2009801547145A patent/CN102281871A/zh active Pending
- 2009-12-03 RS RS20140111A patent/RS53201B/sr unknown
- 2009-12-03 MX MX2011005643A patent/MX2011005643A/es active IP Right Grant
- 2009-12-03 BR BRPI0922806A patent/BRPI0922806B8/pt not_active IP Right Cessation
- 2009-12-03 WO PCT/EP2009/008857 patent/WO2010063493A1/en not_active Ceased
-
2011
- 2011-05-24 ZA ZA2011/03791A patent/ZA201103791B/en unknown
- 2011-05-31 IL IL213270A patent/IL213270A/en active IP Right Grant
- 2011-06-28 CO CO11080792A patent/CO6400183A2/es not_active Application Discontinuation
-
2013
- 2013-07-01 US US13/932,785 patent/US20140018334A1/en not_active Abandoned
-
2014
- 2014-03-05 CY CY20141100174T patent/CY1114977T1/el unknown
- 2014-04-22 SM SM201400053T patent/SMT201400053B/xx unknown
-
2015
- 2015-04-24 US US14/695,527 patent/US20150335588A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,467 patent/US10543196B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510484A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140204T1 (hr) | Oralni oblici doziranja bendamustina | |
| JP6938462B2 (ja) | 治療用化合物の脳への一方向送達のためのインプラント組成物 | |
| TWI841481B (zh) | 乳酸鈣組成物及使用方法 | |
| JP2020528880A5 (cg-RX-API-DMAC7.html) | ||
| MY173881A (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
| CN118903436A (zh) | 治疗肥大细胞增多症的组合疗法 | |
| AU2018215336A1 (en) | Methods for treating cancer using HSP90 inhibitors | |
| TW200924756A (en) | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease | |
| CN109475524A (zh) | 用于减少中性粒细胞减少症的组合物和方法 | |
| JP2018503610A5 (cg-RX-API-DMAC7.html) | ||
| KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| KR20210010524A (ko) | 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 | |
| JP2021178839A (ja) | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 | |
| JP6170946B2 (ja) | ロミデプシン製剤及びその使用 | |
| WO2024102187A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| CN110831592A (zh) | 医药 | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| TW202425975A (zh) | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 | |
| Rummel | German experience with bendamustine treating Relapsed/Refractory indolent B-Cell and mantle cell lymphomas | |
| CN112535688A (zh) | 药物组合 | |
| CN121219284A (zh) | 治疗具有促细胞分裂原活化蛋白激酶(mapk)通路改变的实体瘤的方法 | |
| CN105228611B (zh) | 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合 | |
| US20060205795A1 (en) | Cancer treatment with epothilones |